Score Overview
Explore the 2021 public Archive ranking →
Where Arrowhead Pharmaceuticals Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. ARWR does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 66.25 | — |
1 Year2025-09-29 | $ 33.78 | 96.12% |
5 Years2021-09-29 | $ 60.63 | 9.27% |
10 Years2016-09-29 | $ 7.30 | 9x |
20 Years2006-09-29 | $ 49.90 | 32.77% |
30 Years1996-09-25 | $ 203.13 | -67.38% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | 30 Years1996-09-25 |
|---|---|---|---|---|---|---|
| Price | $ 66.25 | $ 33.78 | $ 60.63 | $ 7.30 | $ 49.90 | $ 203.13 |
| Return | — | 96.12% | 9.27% | 9x | 32.77% | -67.38% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 669M | -$ 319M | $ 1.60B |
| 2025 | $ 829M | $ 919M | |
| 2024 | $ 3M | -$ 599M | $ 680M |
| 2023 | $ 240M | -$ 205M | $ 403M |
| 2022 | $ 243M | -$ 176M | $ 376M |
| 2021 | $ 138M | -$ 140M | $ 367M |
| 2020 | $ 87M | -$ 84M | $ 315M |
| 2019 | $ 168M | $ 67M | $ 258M |
| 2018 | $ 16M | -$ 54M | $ 76M |
| 2017 | $ 31M | -$ 34M | $ 65M |
| 2016 | -$ 81M | $ 85M | |
| 2015 | $ 382K | -$ 91M | $ 98M |
| 2014 | $ 175K | -$ 58M | $ 154M |
| 2013 | $ 290.27K | -$ 31M | $ 28M |
| 2012 | $ 146.88K | -$ 21M | $ 3M |
| 2011 | $ 296.14K | -$ 3M | $ 8M |
| 2010 | $ 620.1K | -$ 5M | $ 6M |
| 2009 | $ 3M | -$ 19M | $ 2M |
| 2008 | $ 1M | -$ 27M | $ 10M |
| 2007 | $ 1M | -$ 29M | $ 24M |
| 2006 | $ 595.46K | -$ 18M | $ 28M |
| 2005 | $ 590.68K | -$ 6M | $ 22M |
| 2004 | $ 196.31K | -$ 2M | $ 9M |
| 2003 | -$ 95.24K | $ 1M | |
| 2002 | $ 2.27K | -$ 246.21K | $ 18.49K |
| 2001 | $ 9.31K | -$ 185.82K | $ 271.00 |
| 2000 | $ 24.88K | -$ 137.55K | $ 1.95K |
| 1999 | $ 37K | $ 593K | $ 124.00 |
| 1998 | $ 60.38K | -$ 165.03K | $ 1.02K |
| 1997 | $ 76.59K | -$ 854.53K | $ 1.17K |
Arrowhead Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 87M to $ 829M. Revenue increased in 2 of those 5 years; net income in 0.
Across Arrowhead Pharmaceuticals Inc's full reported history, from 1997 to 2025, revenue grew from $ 76.59K to $ 829M. Revenue increased in 44% of the years measured; net income in 37%.
Arrowhead Pharmaceuticals Inc currently holds a 20-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.
Membership
Explore ARWR with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
